It all started with a Vision. Vision to be one of the most respected, profitable and integrated Pharma Company of the world, which can match international standards on all counts. We are working towards our Vision with full enthusiasm and commitment. As a result today, Marksans Pharma Ltd. has already made its presence felt in the arena of the pharmaceutical world.

To achieve that objective it needs intelligent anticipation of emerging markets which have maximum potential, as well as review of the increasing needs of developing markets.

To envision the Global markets, MPL labs built up a state of the art plant spreading over 18000 sq meters in Goa. The US FDA compliant plant was commissioned in 2001- 02 and received the Australian TGA, UK MHRA and Brazilian ANVISA approval by May 2003.

Marksans Pharma Ltd. has achieved remarkable growth during the past two years. Starting with exports to unregulated markets, the company has successively penetrated into the regulated markets. Main focus markets for Marksans is United Kingdom, Australia, New Zealand, Germany and other European markets. Marksans is also eying to tab huge Russian and CIS markets and has initiated dossier filling in these countries.

With the approval of Prestigious UK MHRA, Marksans has actively started exporting formulation to UK. Marksans has tied up with renowned players in UK markets for the supply of OTC as well as prescription products. About 70 % of export turnover is from United Kingdom. Besides, Acquisition of Hale group Ltd. has given more muscle to Marksans in UK market.

The business model also involves registration of its own dossiers and developing products going off patent 2005 onwards. MPL has already registered 5 products in the Australian markets. MPL also is applying for registration of drugs which are shortly going off patent in Australia. ANZ is the 2nd highest revenue earner for exports after UK.

Marksans is also expanding its business in rest of the European markets through Contract manufacturing and active product registrations. Marksans has a strong back up in terms of its formulation development and R & D team aligning itself to aggressive marketing strategies.

Marksans has plans to be a very aggressive player in the International field and aspire to get US FDA approval by this year.